How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "2490"
  ["article_id"]=>
  string(4) "2490"
  [1]=>
  string(100) "Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma"
  ["article_title"]=>
  string(100) "Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma"
  [2]=>
  string(150) "FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on"
  ["short_description"]=>
  string(150) "FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on"
  [3]=>
  string(246) "FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today..."
  ["description"]=>
  string(246) "FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(283) "https://www.drugs.com/clinical_trials/cellectar-receives-fda-fast-track-designation-clr-131-relapsed-refractory-multiple-myeloma-18141.html?utm_source=ddc&utm_medium=rss&utm_campaign=Cellectar+Receives+FDA+Fast+Track+Designation+for+CLR+131+in+Relapsed+or+Refractory+Multiple+Myeloma"
  ["blog_url"]=>
  string(283) "https://www.drugs.com/clinical_trials/cellectar-receives-fda-fast-track-designation-clr-131-relapsed-refractory-multiple-myeloma-18141.html?utm_source=ddc&utm_medium=rss&utm_campaign=Cellectar+Receives+FDA+Fast+Track+Designation+for+CLR+131+in+Relapsed+or+Refractory+Multiple+Myeloma"
  [15]=>
  string(19) "2019-05-14 07:05:05"
  ["add_date"]=>
  string(19) "2019-05-14 07:05:05"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:34"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multip

FLORHAM PARK, N.J., May 13, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopha

array(40) {
  [0]=>
  string(4) "2472"
  ["article_id"]=>
  string(4) "2472"
  [1]=>
  string(68) " FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy"
  ["article_title"]=>
  string(68) " FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy"
  [2]=>
  string(150) "TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has app"
  ["short_description"]=>
  string(150) "TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has app"
  [3]=>
  string(250) "TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby..."
  ["description"]=>
  string(250) "TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection to treat all stages of diabetic retinopathy (DR), and thereby..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(208) "https://www.drugs.com/newdrugs/fda-approves-eylea-aflibercept-diabetic-retinopathy-4968.html?utm_source=ddc&utm_medium=rss&utm_campaign=+FDA+Approves+Eylea+%28aflibercept%29+Injection+for+Diabetic+Retinopathy"
  ["blog_url"]=>
  string(208) "https://www.drugs.com/newdrugs/fda-approves-eylea-aflibercept-diabetic-retinopathy-4968.html?utm_source=ddc&utm_medium=rss&utm_campaign=+FDA+Approves+Eylea+%28aflibercept%29+Injection+for+Diabetic+Retinopathy"
  [15]=>
  string(19) "2019-05-14 06:05:44"
  ["add_date"]=>
  string(19) "2019-05-14 06:05:44"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

FDA Approves Eylea (aflibercept) Injection for Diabetic Retinopathy

TARRYTOWN, N.Y., May 13, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Dru

array(40) {
  [0]=>
  string(4) "2473"
  ["article_id"]=>
  string(4) "2473"
  [1]=>
  string(127) "Lilly's Cyramza (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma"
  ["article_title"]=>
  string(127) "Lilly's Cyramza (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma"
  [2]=>
  string(150) "INDIANAPOLIS, May 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has appr"
  ["short_description"]=>
  string(150) "INDIANAPOLIS, May 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has appr"
  [3]=>
  string(249) "INDIANAPOLIS, May 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of..."
  ["description"]=>
  string(249) "INDIANAPOLIS, May 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved Cyramza (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(1) "8"
  ["rss_id"]=>
  string(1) "8"
  [14]=>
  string(300) "https://www.drugs.com/newdrugs/lilly-s-cyramza-ramucirumab-becomes-first-fda-approved-biomarker-driven-therapy-patients-4960.html?utm_source=ddc&utm_medium=rss&utm_campaign=Lilly%27s+Cyramza+%28ramucirumab%29+Becomes+First+FDA-Approved+Biomarker-Driven+Therapy+in+Patients+with+Hepatocellular+Carcino"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/newdrugs/lilly-s-cyramza-ramucirumab-becomes-first-fda-approved-biomarker-driven-therapy-patients-4960.html?utm_source=ddc&utm_medium=rss&utm_campaign=Lilly%27s+Cyramza+%28ramucirumab%29+Becomes+First+FDA-Approved+Biomarker-Driven+Therapy+in+Patients+with+Hepatocellular+Carcino"
  [15]=>
  string(19) "2019-05-14 04:05:44"
  ["add_date"]=>
  string(19) "2019-05-14 04:05:44"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:27"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:27"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lilly's Cyramza (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in P

INDIANAPOLIS, May 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug

array(40) {
  [0]=>
  string(4) "2790"
  ["article_id"]=>
  string(4) "2790"
  [1]=>
  string(57) "Choosing The Right QMS For Your Medical Device Company"
  ["article_title"]=>
  string(57) "Choosing The Right QMS For Your Medical Device Company"
  [2]=>
  string(153) "Going paperless is easier than you think.&#nlThe post Choosing The Right QMS For Your Medical Device Company appeared first on MedTech Intelligence."
  ["short_description"]=>
  string(153) "Going paperless is easier than you think.&#nlThe post Choosing The Right QMS For Your Medical Device Company appeared first on MedTech Intelligence."
  [3]=>
  string(396) "
Going paperless is easier than you think.
&#nl
The post Choosing The Right QMS For Your Medical Device Company appeared first on MedTech Intelligence.
&#nl"
  ["description"]=>
  string(396) "
Going paperless is easier than you think.
&#nl
The post Choosing The Right QMS For Your Medical Device Company appeared first on MedTech Intelligence.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "98"
  ["rss_id"]=>
  string(2) "98"
  [14]=>
  string(98) "https://www.medtechintelligence.com/column/choosing-the-right-qms-for-your-medical-device-company/"
  ["blog_url"]=>
  string(98) "https://www.medtechintelligence.com/column/choosing-the-right-qms-for-your-medical-device-company/"
  [15]=>
  string(19) "2019-05-14 00:39:06"
  ["add_date"]=>
  string(19) "2019-05-14 00:39:06"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:07"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:07"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Choosing The Right QMS For Your Medical Device Company

Going paperless is easier than you think.

&#nl

The post 

array(40) {
  [0]=>
  string(4) "2656"
  ["article_id"]=>
  string(4) "2656"
  [1]=>
  string(69) "Immunologix boosts Translational Sciences division with new recruits "
  ["article_title"]=>
  string(69) "Immunologix boosts Translational Sciences division with new recruits "
  [2]=>
  string(150) "Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Trans"
  ["short_description"]=>
  string(150) "Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Trans"
  [3]=>
  string(177) "Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division."
  ["description"]=>
  string(177) "Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs created from the launch of its Translational Sciences division."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "49"
  ["rss_id"]=>
  string(2) "49"
  [14]=>
  string(174) "https://www.outsourcing-pharma.com/Article/2019/05/13/Immunologix-boosts-Translational-Sciences-division-with-new-recruits?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(174) "https://www.outsourcing-pharma.com/Article/2019/05/13/Immunologix-boosts-Translational-Sciences-division-with-new-recruits?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-14 00:23:00"
  ["add_date"]=>
  string(19) "2019-05-14 00:23:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:24"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:24"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Immunologix boosts Translational Sciences division with new recruits

Immunologix bolsters its scientific expertise with two new hires to build on its bioanalytical biomarker programs create

array(40) {
  [0]=>
  string(4) "2630"
  ["article_id"]=>
  string(4) "2630"
  [1]=>
  string(83) "Simtec Silicone Parts adds smart clean room for custom medical device manufacturing"
  ["article_title"]=>
  string(83) "Simtec Silicone Parts adds smart clean room for custom medical device manufacturing"
  [2]=>
  string(143) "Simtec Silicone Parts, a US-based liquid silicone rubber (LSR) and LSR multi-shot injection moulding specialist has added a class 8 clean room."
  ["short_description"]=>
  string(143) "Simtec Silicone Parts, a US-based liquid silicone rubber (LSR) and LSR multi-shot injection moulding specialist has added a class 8 clean room."
  [3]=>
  string(143) "Simtec Silicone Parts, a US-based liquid silicone rubber (LSR) and LSR multi-shot injection moulding specialist has added a class 8 clean room."
  ["description"]=>
  string(143) "Simtec Silicone Parts, a US-based liquid silicone rubber (LSR) and LSR multi-shot injection moulding specialist has added a class 8 clean room."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(115) "https://www.medicalplasticsnews.com/mpn-north-america/simtec-adds-smart-clean-room-for-custom-medical-device-manuf/"
  ["blog_url"]=>
  string(115) "https://www.medicalplasticsnews.com/mpn-north-america/simtec-adds-smart-clean-room-for-custom-medical-device-manuf/"
  [15]=>
  string(19) "2019-05-13 23:43:18"
  ["add_date"]=>
  string(19) "2019-05-13 23:43:18"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:19"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Simtec Silicone Parts adds smart clean room for custom medical device manufacturing

Simtec Silicone Parts, a US-based liquid silicone rubber (LSR) and LSR multi-shot injection moulding specialist has adde

array(40) {
  [0]=>
  string(4) "2801"
  ["article_id"]=>
  string(4) "2801"
  [1]=>
  string(71) "Takeda and Regeneron continue to tap into Adimab’s capabilities "
  ["article_title"]=>
  string(71) "Takeda and Regeneron continue to tap into Adimab’s capabilities "
  [2]=>
  string(137) "Adimab expands partnerships with Takeda and Regeneron to enable biopharmaceutical companies with discovery and optimization capabilities."
  ["short_description"]=>
  string(137) "Adimab expands partnerships with Takeda and Regeneron to enable biopharmaceutical companies with discovery and optimization capabilities."
  [3]=>
  string(137) "Adimab expands partnerships with Takeda and Regeneron to enable biopharmaceutical companies with discovery and optimization capabilities."
  ["description"]=>
  string(137) "Adimab expands partnerships with Takeda and Regeneron to enable biopharmaceutical companies with discovery and optimization capabilities."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(3) "107"
  ["rss_id"]=>
  string(3) "107"
  [14]=>
  string(169) "https://www.outsourcing-pharma.com/Article/2019/05/13/Takeda-and-Regeneron-continue-to-tap-into-Adimab-s-capabilities?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  ["blog_url"]=>
  string(169) "https://www.outsourcing-pharma.com/Article/2019/05/13/Takeda-and-Regeneron-continue-to-tap-into-Adimab-s-capabilities?utm_source=RSS_Feed&utm_medium=RSS&utm_campaign=RSS"
  [15]=>
  string(19) "2019-05-13 23:32:00"
  ["add_date"]=>
  string(19) "2019-05-13 23:32:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:25:13"
  ["create_at"]=>
  string(19) "2019-05-23 14:25:13"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Takeda and Regeneron continue to tap into Adimab’s capabilities

Adimab expands partnerships with Takeda and Regeneron to enable biopharmaceutical companies with discovery and optimizat

array(40) {
  [0]=>
  string(4) "2544"
  ["article_id"]=>
  string(4) "2544"
  [1]=>
  string(40) "Coloplast aktietilbagekøb uge 19/2019"
  ["article_title"]=>
  string(40) "Coloplast aktietilbagekøb uge 19/2019"
  [2]=>
  string(30) "Selskabsmeddelelse13. maj 2019"
  ["short_description"]=>
  string(30) "Selskabsmeddelelse13. maj 2019"
  [3]=>
  string(75) "
Selskabsmeddelelse
13. maj 2019
"
  ["description"]=>
  string(75) "
Selskabsmeddelelse
13. maj 2019
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(113) "http://www.globenewswire.com/news-release/2019/05/13/1822631/0/da/Coloplast-aktietilbagek%C3%B8b-uge-19-2019.html"
  ["blog_url"]=>
  string(113) "http://www.globenewswire.com/news-release/2019/05/13/1822631/0/da/Coloplast-aktietilbagek%C3%B8b-uge-19-2019.html"
  [15]=>
  string(19) "2019-05-13 22:13:00"
  ["add_date"]=>
  string(19) "2019-05-13 22:13:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:54"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Coloplast aktietilbagekøb uge 19/2019

Selskabsmeddelelse
13. maj 2019

array(40) {
  [0]=>
  string(4) "2543"
  ["article_id"]=>
  string(4) "2543"
  [1]=>
  string(37) "Coloplast share buy-back week 19/2019"
  ["article_title"]=>
  string(37) "Coloplast share buy-back week 19/2019"
  [2]=>
  string(72) "Announcement             13 May 2019"
  ["short_description"]=>
  string(72) "Announcement             13 May 2019"
  [3]=>
  string(134) "
Announcement             
13 May 2019
"
  ["description"]=>
  string(134) "
Announcement             
13 May 2019
"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "27"
  ["rss_id"]=>
  string(2) "27"
  [14]=>
  string(108) "http://www.globenewswire.com/news-release/2019/05/13/1822631/0/en/Coloplast-share-buy-back-week-19-2019.html"
  ["blog_url"]=>
  string(108) "http://www.globenewswire.com/news-release/2019/05/13/1822631/0/en/Coloplast-share-buy-back-week-19-2019.html"
  [15]=>
  string(19) "2019-05-13 22:13:00"
  ["add_date"]=>
  string(19) "2019-05-13 22:13:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:54"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Coloplast share buy-back week 19/2019

Announcement             
13 May 201

array(40) {
  [0]=>
  string(4) "2631"
  ["article_id"]=>
  string(4) "2631"
  [1]=>
  string(83) "Renishaw to present its additive manufacturing capabilities during RAPID + TCT show"
  ["article_title"]=>
  string(83) "Renishaw to present its additive manufacturing capabilities during RAPID + TCT show"
  [2]=>
  string(147) "Renishaw is returning to RAPID + TCT, the additive manufacturing (AM) and 3D printing event to share its expertise in medical device manufacturing."
  ["short_description"]=>
  string(147) "Renishaw is returning to RAPID + TCT, the additive manufacturing (AM) and 3D printing event to share its expertise in medical device manufacturing."
  [3]=>
  string(147) "Renishaw is returning to RAPID + TCT, the additive manufacturing (AM) and 3D printing event to share its expertise in medical device manufacturing."
  ["description"]=>
  string(147) "Renishaw is returning to RAPID + TCT, the additive manufacturing (AM) and 3D printing event to share its expertise in medical device manufacturing."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "41"
  ["rss_id"]=>
  string(2) "41"
  [14]=>
  string(114) "https://www.medicalplasticsnews.com/mpn-north-america/renishaw-to-present-its-additive-manufacturing-capabilities/"
  ["blog_url"]=>
  string(114) "https://www.medicalplasticsnews.com/mpn-north-america/renishaw-to-present-its-additive-manufacturing-capabilities/"
  [15]=>
  string(19) "2019-05-13 19:32:39"
  ["add_date"]=>
  string(19) "2019-05-13 19:32:39"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:19"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:19"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Renishaw to present its additive manufacturing capabilities during RAPID + TCT show

Renishaw is returning to RAPID + TCT, the additive manufacturing (AM) and 3D printing event to share its expertise in me

array(40) {
  [0]=>
  string(4) "2764"
  ["article_id"]=>
  string(4) "2764"
  [1]=>
  string(159) "Medidata NEXT London 2019: Blending the Best of Clinical Development, AI-Enabled Platform Demonstrations and Regulatory Compliance for Leaders in Life Sciences"
  ["article_title"]=>
  string(159) "Medidata NEXT London 2019: Blending the Best of Clinical Development, AI-Enabled Platform Demonstrations and Regulatory Compliance for Leaders in Life Sciences"
  [2]=>
  string(150) "Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market d"
  ["short_description"]=>
  string(150) "Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market d"
  [3]=>
  string(571) "Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market developmentsNovartis, IQVIA, Syneos Health, UK Office for Life Sciences, NIHR, Deloitte and more keynote speakers to share unique insights Conference breakouts offer attendees interactive, hands-on learning opportunities to design, conduct, manage, and monitor the next generation of clinical research studiesLONDON, May 13 2019: Registration is open for Medidata’s NEXT London, the second...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(571) "Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market developmentsNovartis, IQVIA, Syneos Health, UK Office for Life Sciences, NIHR, Deloitte and more keynote speakers to share unique insights Conference breakouts offer attendees interactive, hands-on learning opportunities to design, conduct, manage, and monitor the next generation of clinical research studiesLONDON, May 13 2019: Registration is open for Medidata’s NEXT London, the second...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(89) "http://www.realwire.com/releases/Blending-the-Best-of-Clinical-Development-Demonstrations"
  ["blog_url"]=>
  string(89) "http://www.realwire.com/releases/Blending-the-Best-of-Clinical-Development-Demonstrations"
  [15]=>
  string(19) "2019-05-13 17:00:00"
  ["add_date"]=>
  string(19) "2019-05-13 17:00:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:49"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:49"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Medidata NEXT London 2019: Blending the Best of Clinical Development, AI-Enabled Platform

Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ah

array(40) {
  [0]=>
  string(4) "2491"
  ["article_id"]=>
  string(4) "2491"
  [1]=>
  string(193) "Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs"
  ["article_title"]=>
  string(193) "Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With Seltorexant (MIN-202) in Treatment of Depressed Patients With an Inadequate Response to SSRIs and SNRIs"
  [2]=>
  string(150) "WALTHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the"
  ["short_description"]=>
  string(150) "WALTHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the"
  [3]=>
  string(252) "WALTHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced positive..."
  ["description"]=>
  string(252) "WALTHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced positive..."
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "15"
  ["rss_id"]=>
  string(2) "15"
  [14]=>
  string(300) "https://www.drugs.com/clinical_trials/minerva-neurosciences-announces-positive-top-line-results-phase-2b-clinical-trial-seltorexant-min-18142.html?utm_source=ddc&utm_medium=rss&utm_campaign=Minerva+Neurosciences+Announces+Positive+Top+Line+Results+in+Phase+2b+Clinical+Trial+With+Seltorexant+%28MIN-2"
  ["blog_url"]=>
  string(300) "https://www.drugs.com/clinical_trials/minerva-neurosciences-announces-positive-top-line-results-phase-2b-clinical-trial-seltorexant-min-18142.html?utm_source=ddc&utm_medium=rss&utm_campaign=Minerva+Neurosciences+Announces+Positive+Top+Line+Results+in+Phase+2b+Clinical+Trial+With+Seltorexant+%28MIN-2"
  [15]=>
  string(19) "2019-05-13 08:05:00"
  ["add_date"]=>
  string(19) "2019-05-13 08:05:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:18:34"
  ["create_at"]=>
  string(19) "2019-05-23 14:18:34"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Minerva Neurosciences Announces Positive Top Line Results in Phase 2b Clinical Trial With

WALTHAM, Mass., May 13, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmac